EIDX Eidos Therapeutics Inc.

36.23
-0.52  -1%
Previous Close 36.75
Open 36.83
Price To Book 10.29
Market Cap 1,356,463,808
Shares 37,440,348
Volume 117,210
Short Ratio
Av. Daily Volume 180,930
Stock charts supplied by TradingView

NewsSee all news

  1. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  2. Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin

  3. Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at

  4. Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

    Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (NASDAQ:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the

  5. Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX

    PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ:EIDX) on behalf of the company's shareholders.  The investigation seeks to determine whether

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2021.
AG10 / BBP-265 - ATTRibute-CM
ATTR-CM
Phase 3 trial planned for 2H 2019.
AG10 / BBP-265
ATTR-PN
Phase 2 data to be presented at AHA November 16, 2019, 5:30 PM ET.
AG10 / BBP-265 - open label
ATTR-CM

Latest News

  1. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  2. Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin

  3. Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at

  4. Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

    Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (NASDAQ:EIDX) ("Eidos") announced today that the Special Committee of its Board of Directors (the "Special Committee") unanimously rejected the

  5. Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX

    PHILADELPHIA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ:EIDX) on behalf of the company's shareholders.  The investigation seeks to determine whether